Item 5. Other Information
Item 5. Other Information
During the fiscal quarter ended June 30, 2026, none of the Company’s directors or officers adopted , modified , or terminated a Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
Item 6. Exhibits
No.
Description
31.1
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*
31.2
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Financial Officer*
32.1
Section 1350 Certification of Chief Executive Officer**
32.2
Section 1350 Certification of Chief Financial Officer**
101.INS
Inline XBRL Instance Document.
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
*
Filed herewith.
**
Furnished herewith.
21
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
INmune Bio Inc.
Date: August 6, 2026
By:
/s/ David Moss
David Moss
Chief Executive Officer
(Principal Executive Officer)
Date: August 6, 2026
By:
/s/ Cory Ellspermann
Cory Ellspermann
Chief Financial Officer
(Principal Financial and Accounting Officer)
22
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.